| Budget Amount *help |
¥18,460,000 (Direct Cost: ¥14,200,000、Indirect Cost: ¥4,260,000)
Fiscal Year 2015: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
Fiscal Year 2013: ¥6,890,000 (Direct Cost: ¥5,300,000、Indirect Cost: ¥1,590,000)
|
|---|
| Outline of Final Research Achievements |
In this study, we have explored to develop non-inhibitory chaperone compounds for human beta-galactosidase deficiency. Screening of the compound library found two candidates, which showed stabilization activity to beta-galactosidase enzyme in vitro without substrate competitive inhibition activity. We also identified a new chaperone candidate, conduramine-F4 based on a lead compound, NOEV. This compound showed a decreased inhibitory activity and increased enzyme enhancing activity against human beta-galactosidase in vitro, indidated as a new chaperone candidate for this disease.
|
